The highest diagnostic performance was demonstrated for ApoA4, LRG 1, and ApoA2 with AUROC 0.9, 0.89, and 0.87, respectively (Table 1, Figure 2), which can be explained by their good performance in patients with both early and advanced stages; as expected, CRC-specific biomarkers, such as CEA and CA 19-9 demonstrated good performance only in CRC patients with advanced stages. Here, APOA2 is linked to colorectal carcinoma.